Cargando…
Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide
Type 2 diabetes makes up approximately 85% of all diabetic cases and it is linked to approximately one-third of all hospitalisations. Newer therapies with long-acting biologics such as glucagon-like peptide-1 (GLP-1) analogues have been promising in managing the disease, but they cannot reverse the...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723263/ https://www.ncbi.nlm.nih.gov/pubmed/31430872 http://dx.doi.org/10.3390/pharmaceutics11080418 |
_version_ | 1783448727289069568 |
---|---|
author | Abeer, Muhammad Mustafa Meka, Anand Kumar Pujara, Naisarg Kumeria, Tushar Strounina, Ekaterina Nunes, Rute Costa, Ana Sarmento, Bruno Hasnain, Sumaira Z. Ross, Benjamin P. Popat, Amirali |
author_facet | Abeer, Muhammad Mustafa Meka, Anand Kumar Pujara, Naisarg Kumeria, Tushar Strounina, Ekaterina Nunes, Rute Costa, Ana Sarmento, Bruno Hasnain, Sumaira Z. Ross, Benjamin P. Popat, Amirali |
author_sort | Abeer, Muhammad Mustafa |
collection | PubMed |
description | Type 2 diabetes makes up approximately 85% of all diabetic cases and it is linked to approximately one-third of all hospitalisations. Newer therapies with long-acting biologics such as glucagon-like peptide-1 (GLP-1) analogues have been promising in managing the disease, but they cannot reverse the pathology of the disease. Additionally, their parenteral administration is often associated with high healthcare costs, risk of infections, and poor patient adherence associated with phobia of needles. Oral delivery of these compounds would significantly improve patient compliance; however, poor enzymatic stability and low permeability across the gastrointestinal tract makes this task challenging. In the present work, large pore dendritic silica nanoparticles (DSNPs) with a pore size of ~10 nm were prepared, functionalized, and optimized in order to achieve high peptide loading and improve intestinal permeation of exenatide, a GLP-1 analogue. Compared to the loading capacity of the most popular, Mobil Composition of Matter No. 41 (MCM-41) with small pores, DSNPs showed significantly high loading owing to their large and dendritic pore structure. Among the tested DSNPs, pristine and phosphonate-modified DSNPs (PDSNPs) displayed remarkable loading of 40 and 35% w/w, respectively. Furthermore, particles successfully coated with positively charged chitosan reduced the burst release of exenatide at both pH 1.2 and 6.8. Compared with free exenatide, both chitosan-coated and uncoated PDSNPs enhanced exenatide transport through the Caco-2 monolayer by 1.7 fold. Interestingly, when a triple co-culture model of intestinal permeation was used, chitosan-coated PDSNPs performed better compared to both PDSNPs and free exenatide, which corroborated our hypothesis behind using chitosan to interact with mucus and improve permeation. These results indicate the emerging role of large pore silica nanoparticles as promising platforms for oral delivery of biologics such as exenatide. |
format | Online Article Text |
id | pubmed-6723263 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-67232632019-09-10 Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide Abeer, Muhammad Mustafa Meka, Anand Kumar Pujara, Naisarg Kumeria, Tushar Strounina, Ekaterina Nunes, Rute Costa, Ana Sarmento, Bruno Hasnain, Sumaira Z. Ross, Benjamin P. Popat, Amirali Pharmaceutics Article Type 2 diabetes makes up approximately 85% of all diabetic cases and it is linked to approximately one-third of all hospitalisations. Newer therapies with long-acting biologics such as glucagon-like peptide-1 (GLP-1) analogues have been promising in managing the disease, but they cannot reverse the pathology of the disease. Additionally, their parenteral administration is often associated with high healthcare costs, risk of infections, and poor patient adherence associated with phobia of needles. Oral delivery of these compounds would significantly improve patient compliance; however, poor enzymatic stability and low permeability across the gastrointestinal tract makes this task challenging. In the present work, large pore dendritic silica nanoparticles (DSNPs) with a pore size of ~10 nm were prepared, functionalized, and optimized in order to achieve high peptide loading and improve intestinal permeation of exenatide, a GLP-1 analogue. Compared to the loading capacity of the most popular, Mobil Composition of Matter No. 41 (MCM-41) with small pores, DSNPs showed significantly high loading owing to their large and dendritic pore structure. Among the tested DSNPs, pristine and phosphonate-modified DSNPs (PDSNPs) displayed remarkable loading of 40 and 35% w/w, respectively. Furthermore, particles successfully coated with positively charged chitosan reduced the burst release of exenatide at both pH 1.2 and 6.8. Compared with free exenatide, both chitosan-coated and uncoated PDSNPs enhanced exenatide transport through the Caco-2 monolayer by 1.7 fold. Interestingly, when a triple co-culture model of intestinal permeation was used, chitosan-coated PDSNPs performed better compared to both PDSNPs and free exenatide, which corroborated our hypothesis behind using chitosan to interact with mucus and improve permeation. These results indicate the emerging role of large pore silica nanoparticles as promising platforms for oral delivery of biologics such as exenatide. MDPI 2019-08-19 /pmc/articles/PMC6723263/ /pubmed/31430872 http://dx.doi.org/10.3390/pharmaceutics11080418 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Abeer, Muhammad Mustafa Meka, Anand Kumar Pujara, Naisarg Kumeria, Tushar Strounina, Ekaterina Nunes, Rute Costa, Ana Sarmento, Bruno Hasnain, Sumaira Z. Ross, Benjamin P. Popat, Amirali Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide |
title | Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide |
title_full | Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide |
title_fullStr | Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide |
title_full_unstemmed | Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide |
title_short | Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide |
title_sort | rationally designed dendritic silica nanoparticles for oral delivery of exenatide |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723263/ https://www.ncbi.nlm.nih.gov/pubmed/31430872 http://dx.doi.org/10.3390/pharmaceutics11080418 |
work_keys_str_mv | AT abeermuhammadmustafa rationallydesigneddendriticsilicananoparticlesfororaldeliveryofexenatide AT mekaanandkumar rationallydesigneddendriticsilicananoparticlesfororaldeliveryofexenatide AT pujaranaisarg rationallydesigneddendriticsilicananoparticlesfororaldeliveryofexenatide AT kumeriatushar rationallydesigneddendriticsilicananoparticlesfororaldeliveryofexenatide AT strouninaekaterina rationallydesigneddendriticsilicananoparticlesfororaldeliveryofexenatide AT nunesrute rationallydesigneddendriticsilicananoparticlesfororaldeliveryofexenatide AT costaana rationallydesigneddendriticsilicananoparticlesfororaldeliveryofexenatide AT sarmentobruno rationallydesigneddendriticsilicananoparticlesfororaldeliveryofexenatide AT hasnainsumairaz rationallydesigneddendriticsilicananoparticlesfororaldeliveryofexenatide AT rossbenjaminp rationallydesigneddendriticsilicananoparticlesfororaldeliveryofexenatide AT popatamirali rationallydesigneddendriticsilicananoparticlesfororaldeliveryofexenatide |